{"entity":{"id":"paper-outback-lancet-oncol-2023","kind":"paper","name":"OUTBACK: adjuvant carboplatin-paclitaxel after chemoradiotherapy for locally advanced cervical cancer","aka":[],"tldr":"Adding four cycles of carboplatin-paclitaxel chemotherapy after standard chemoradiation did not improve survival in locally advanced cervical cancer and caused more side effects, so adjuvant chemotherapy is not recommended.","summary":"Phase 3 trial of 919 women with locally advanced cervical cancer randomised to cisplatin chemoradiotherapy alone or followed by four cycles of adjuvant carboplatin and paclitaxel.\n\nFive-year overall survival was 72 versus 71 percent and progression-free survival 63 versus 61 percent, with more grade 3 to 5 adverse events with adjuvant chemotherapy (81 versus 62 percent) and a fifth of patients never starting it.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2023","url":"https://doi.org/10.1016/S1470-2045(23)00147-X"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37080223/"}],"tags":[],"related":[],"cancers":["locally-advanced-cervical-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["outback"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00147-X","pmid":"37080223","authors":"Mileshkin LR, Moore KN, Barnes EH, et al.","paperType":"rct","findings":["Five-year overall survival 72 percent vs 71 percent.","Grade 3 to 5 adverse events 81 percent vs 62 percent."],"whatItMeans":"Chemotherapy after chemoradiation adds toxicity without benefit; the search for improvement has moved to induction chemotherapy (INTERLACE) and immunotherapy (KEYNOTE-A18).","caveats":["Compliance with adjuvant chemotherapy was incomplete, which may have diluted any effect."],"changedPractice":true,"participants":919},"route":"/key-papers/paper-outback-lancet-oncol-2023/","neighbours":{"cancer":[{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/"}],"trial":[{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}